T-knife Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
T-knife Therapeutics, Inc. - overview
Established
2018
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in Delaware, US, and founded in 2018 by CEO Thomas Blankenstein and CTO Elisa Kieback, T-Knife GmbH is a biopharmaceutical firm that creates treatments for T cell receptors (TCRs). In April 2021, T-Knife GmbH raised USD 110 million in Series B funding led by Fidelity Investments, with participation from CaaS Capital Management, Casdin Capital, Life Sciences Partners, Qatar Investment Authority, Sixty Degree Capital, Andera Partners, RA Capital, and Versant Ventures also participated in the round. T-Knife GmbH secured USD 110 million in Series B investment sponsored by Fidelity Investments in August 2021. The company is a T-cell receptor (TCR) firm that is developing a pipeline of novel medicines for patients with solid tumors.
T-knife is leveraging its proprietary HuTCR transgenic mouse platform to discover and develop a portfolio of TCR-T programs to treat patients with solid tumors. The company’s lead program, TK-8001, is a novel TCR-T product targeting MAGE-A1-positive cancers. T-knife is also developing a pipeline of potential TCR therapeutics against targets with unmet medical needs, including cancer-testis antigens, viral antigens, and commonly shared neoantigens.
Current Investors
Andera Partners, Versant Ventures, Boehringer Ingelheim Venture
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.t-knife.com
Verticals
Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.